沙利文发布《全球及中国瓣膜性心脏病医疗器械行业市场研究报告》
Frost & Sullivan Releases the " Global and China Valvular Heart Disease Medical Device Industry Market Research Report"
瓣膜性心脏病具有患者基数大、疾病负担持续上升及未满足临床需求显著等特点。随着全球人口老龄化加深，以及疾病筛查、影像诊断和规范化治疗能力不断提升，瓣膜性心脏病患者的治疗需求正持续释放。传统外科手术仍是重要治疗方式，但部分高龄、合并症较多或外科手术风险较高的患者难以接受开胸治疗。经导管介入治疗凭借创伤较小、恢复周期较短及适用人群持续扩展等特点，正推动瓣膜性心脏病治疗由以外科手术为主逐步向外科与介入治疗并行的模式演进。
经导管介入治疗人工瓣膜市场正处于由主动脉瓣成熟放量向多瓣位协同发展的阶段。经导管主动脉瓣置换已成为目前商业化程度较高的细分领域，临床应用逐步由高风险患者向更广泛人群延伸。经导管二尖瓣和三尖瓣介入治疗仍处于临床证据积累与商业化导入阶段，随着产品供给不断丰富、适应证逐步明确及临床操作经验持续积累，有望成为行业的重要增长来源。同时，随着既往植入生物瓣膜逐步进入结构性退化周期，瓣中瓣治疗所对应的长期再干预需求亦将持续释放，推动瓣膜介入治疗市场形成覆盖首次治疗与再次干预的全生命周期发展格局。
未来，瓣膜性心脏病医疗器械行业的增长将主要由患者治疗需求扩张、经导管治疗渗透率提升、适应证拓展、产品持续迭代及临床中心能力建设共同驱动。行业竞争亦将由单一产品性能比较逐步转向对技术平台、临床证据、制造一致性、术者培训及全生命周期风险管理等综合能力的竞争。与此同时，监管体系完善、医保支付改革及高值医用耗材价格治理将进一步影响产品准入、价格体系与市场推广节奏。具备多瓣位产品布局、持续创新能力、完善循证证据体系及规模化商业交付能力的企业，将更有机会在全球瓣膜介入治疗市场的发展过程中建立长期竞争优势。
Valvular heart disease is characterized by a large patient population, a growing disease burden and substantial unmet clinical needs. As the global population continues to age and capabilities in disease screening, imaging diagnosis and standardized treatment improve, demand for valvular heart disease treatment is expected to increase. Open-heart surgery remains an important treatment option, but may not be suitable for certain elderly patients, patients with multiple comorbidities or those at elevated surgical risk. With lower procedural trauma, shorter recovery periods and expanding patient eligibility, transcatheter interventions are driving a gradual shift from a predominantly surgical treatment model toward the parallel development of surgical and interventional approaches.
The transcatheter heart valve market is progressing from the established adoption of aortic valve therapies toward broader development across multiple valve positions. Transcatheter aortic valve replacement is currently one of the more commercially established segments, with clinical use gradually expanding beyond high-risk patients. Transcatheter mitral and tricuspid valve interventions remain at an earlier stage of clinical evidence development and commercialization. As product availability expands, indications become better defined and procedural experience accumulates, these therapies are expected to become important sources of industry growth. Meanwhile, as previously implanted bioprosthetic valves progressively enter the structural deterioration cycle, demand for valve-in-valve reintervention is also expected to increase, supporting the development of a lifecycle treatment framework covering both initial valve treatment and subsequent reintervention.
Future growth in the valvular heart disease medical device industry will be driven by rising treatment demand, higher penetration of transcatheter therapies, broader indications, continued product innovation and the development of qualified treatment centers. Industry competition is also evolving beyond individual product performance toward integrated capabilities encompassing technology platforms, clinical evidence generation, manufacturing consistency, physician training and lifecycle risk management. At the same time, evolving regulatory frameworks, medical insurance payment reforms and pricing policies for high-value medical consumables will continue to shape market access, pricing and the pace of commercialization. Companies with multi-valve product portfolios, sustained innovation capabilities, robust clinical evidence and scalable commercialization infrastructure will be better positioned to establish long-term competitive advantages in the evolving global transcatheter heart valve market.
点击以下链接，查看节选版 报告：
如果您对全球及中国瓣膜性心脏病医疗器械行业有进一步的研究需求，请联系我们：
沙利文 周先生
E-mail: albus.zhou@frostchina.com
